Highest-materiality recent filing
Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026
Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.
All eight director nominees elected with ~61.5M votes each; broker non-votes of ~2.7M.
DSS BioHealth converts Series A Preferred into 60.5M common shares of Impact BioMedical
DSS BioHealth Security converted its Series A Convertible Preferred Stock into 60,496,041 shares of common stock.
Impact BioMedical to issue 31.9M shares to DSS to settle $12M debt
Issued 31,939,778 shares of common stock to DSS Inc. to fully satisfy $12M revolving promissory note from March 2023.
Impact BioMedical (IBO) will merge with Dr Ashleys via a reverse merger; existing Impact shareholders receive 4.80% of the new PubCo's ordinary shares.
DSS withdraws from $13.2M debt conversion agreement; no shares issued
DSS withdrew from Debt Conversion Agreement, originally dated March 24, 2025.
Impact Biomedical settles $8.7M debt with 2.4M shares at $3.60/share
Debt conversion with DSS Inc. settles $8,697,142.80 of the $13,176,477.03 principal balance.
Impact Biomedical appoints Chan Heng Fai Ambrose to board of directors
Appointed March 11, 2025, effective same date; over 45 years financial/equity investment experience.
Impact Biomedical CEO presents investor slide deck on Jan 29, 2025; no details available
Slide package furnished as Exhibit 99.1 not included in filing text; no specifics provided.
Impact Biomedical furnishes investor presentation; no specific financial updates disclosed
COO Mark Suseck began delivering investor presentations on November 4, 2024.
Impact Biomedical enters three-year CEO employment agreement with Frank Heuszel
Term from Oct 3, 2024 to Oct 3, 2027; base salary $200K year 1, $250K years 2 and 3.
Impact Biomedical closes IPO of 1.5M shares at $3.00, net proceeds ~$3.76M
IPO of 1,500,000 common shares at $3.00 per share; net proceeds to company ~$3,764,500 after discounts and expenses.
Director Heng Fai Ambrose Chan resigns; Jason T. Grady appointed to board
Heng Fai Ambrose Chan resigned as director effective June 6, 2024, with no disagreement.
On March 11, 2025, the Board of Directors of the Company appointed Mr. Chan Heng Fai Ambrose to serve as a Director of the Company, effective as of the same date.
Additionally on June 6, 2024, the Board of Directors of the Company appointed Jason T. Grady to serve as a Director of the Company, effective as of the same date.
On June 6, 2024, Heng Fai Ambrose Chan notified Impact Biomedical, Inc. (the “Company”) that he is resigning as a member of the Board of Directors of the Company, effective immediately.
Max materiality 1.00 · Median 0.55 · Most common event other_material